Skip to main
TMDX
TMDX logo

TMDX Stock Forecast & Price Target

TMDX Analyst Ratings

Based on 10 analyst ratings
Buy
Strong Buy 30%
Buy 40%
Hold 30%
Sell 0%
Strong Sell 0%

Bulls say

TransMedics Group Inc. has shown a significant improvement in its operating margins, with a 910 basis points increase year-over-year in 2024, followed by an additional 950 basis points increase in the first half of 2025. The company is benefiting from a growing market, as evidenced by the 7.3% rise in the number of liver, heart, and lung transplants in the U.S. from 2023 to 2024, alongside an upward trend in its market share, which increased from 13.8% in 2023 to 20.9% in 2024. Overall, the positive trajectory in operating margins and market share suggests strong potential for earnings per share (EPS) growth moving forward.

Bears say

TransMedics Group Inc. reported product revenues of $87.7 million, which represented a year-over-year increase of 33.1% but fell approximately $1 million short of consensus estimates, contributing to a weakening market response. The company faces multiple risks including slower adoption of its Organ Care System for lung transplants, increased competition, potential changes in reimbursement that might dampen demand, and regulatory challenges that could impede growth. Furthermore, TransMedics’ shares are currently trading at a notable discount to their historical valuation metrics, indicating potential concerns about the company's future revenue growth and commercialization effectiveness.

TMDX has been analyzed by 10 analysts, with a consensus rating of Buy. 30% of analysts recommend a Strong Buy, 40% recommend Buy, 30% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Transmedics Group Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Transmedics Group Inc (TMDX) Forecast

Analysts have given TMDX a Buy based on their latest research and market trends.

According to 10 analysts, TMDX has a Buy consensus rating as of Dec 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $133, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $133, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Transmedics Group Inc (TMDX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.